promising modification strategy for the optimization of peptide drugs. In this study, five different monosaccharide derivatives (7a-e) were covalently linked to the N-terminal of R-lycosin-I, which yielded five glycopeptides (8a-e). They demonstrated increased or reduced cytotoxicity depending on monosaccharide types, which might be explained by the changes of physicochemical properties. Among all synthesized
糖缀合是用于肽药物优化的有希望的修饰策略。在这项研究中,五个不同的
单糖衍
生物(7a-e)与R-lycosin-I的N端共价连接,产生了五个糖肽(8a-e)。他们显示出取决于单
糖类型的细胞毒性增加或减少,这可以用理化性质的变化来解释。在所有合成的糖肽中,只有8a表现出增加的细胞毒性(IC50 = 9.6±0.3μM)和选择性(IC50 = 37.4±5.9μM)。癌细胞中高表达的
葡萄糖转运蛋白1(GLUT1)被批准参与8a的细胞毒性和选择性增强。此外,在裸鼠异种移植模型中,8a抑制R-lycosin-I抑制肿瘤生长,而不会在腹膜内产生副作用。